[
  {
    "ts": null,
    "headline": "Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock",
    "summary": "Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=85d30aeb470b1773902cb33acd23ecd407d003b240375aa64dc03342cbd6f41d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756848345,
      "headline": "Here is What to Know Beyond Why Abbott Laboratories (ABT) is a Trending Stock",
      "id": 136613013,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=85d30aeb470b1773902cb33acd23ecd407d003b240375aa64dc03342cbd6f41d"
    }
  },
  {
    "ts": null,
    "headline": "Medtronic advances Abbott partnership with FDA nod",
    "summary": "The company received FDA authorization to pair its 780G insulin pump with a glucose sensor made by Abbott, and to use the device for Type 2 diabetes.",
    "url": "https://finnhub.io/api/news?id=ec2a026d69925c0f949f808f26f536d02cc7b2e682344702e3fd97da2981c433",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756829214,
      "headline": "Medtronic advances Abbott partnership with FDA nod",
      "id": 136613014,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "The company received FDA authorization to pair its 780G insulin pump with a glucose sensor made by Abbott, and to use the device for Type 2 diabetes.",
      "url": "https://finnhub.io/api/news?id=ec2a026d69925c0f949f808f26f536d02cc7b2e682344702e3fd97da2981c433"
    }
  },
  {
    "ts": null,
    "headline": "FDA Clears MiniMed™ 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes",
    "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones that broaden the MiniMed™ 780G system portfolio: clearance of the SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with the Instinct sensor, made by Abbott, for type 1 diabetes, and approval of the MiniMed™ 780G system for use in adults 18+ with insulin-requiring type 2 diabetes.",
    "url": "https://finnhub.io/api/news?id=cdd1a772affc212d2b4dba202f99b39d5fe7e5a7a935b1fd594ed0877ac44a6a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756820700,
      "headline": "FDA Clears MiniMed™ 780G System to Enable Integration with the Instinct Sensor, Made by Abbott, and Approves Use in Type 2 Diabetes",
      "id": 136613015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced two U.S. Food and Drug Administration (FDA) regulatory milestones that broaden the MiniMed™ 780G system portfolio: clearance of the SmartGuard™ algorithm as an interoperable automated glycemic controller (iAGC), enabling integration with the Instinct sensor, made by Abbott, for type 1 diabetes, and approval of the MiniMed™ 780G system for use in adults 18+ with insulin-requiring type 2 diabetes.",
      "url": "https://finnhub.io/api/news?id=cdd1a772affc212d2b4dba202f99b39d5fe7e5a7a935b1fd594ed0877ac44a6a"
    }
  },
  {
    "ts": null,
    "headline": "Hemato-Oncology Testing Market Size, Share & Trends Analysis Report 2025-2030 Featuring Key Players Roche, Abbott, EntroGen, Qiagen, and Cepheid (Danaher) Among Others",
    "summary": "Opportunities in the hemato-oncology testing market include rising lymphoma and myeloma cases, personalized therapy demand, and advanced molecular diagnostics. Emerging technologies like single-cell sequencing and long-read sequencing enhance diagnostic precision, thus driving market growth and improving patient outcomes. Hemato Oncology Testing Market Hemato Oncology Testing Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"Hemato-Oncology Testing Market Size, Share & Trends Analysis 2025-",
    "url": "https://finnhub.io/api/news?id=0997936512655a16c9459c76ec16c3092746a3f3b6a86ea25ed3178d34210670",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756817940,
      "headline": "Hemato-Oncology Testing Market Size, Share & Trends Analysis Report 2025-2030 Featuring Key Players Roche, Abbott, EntroGen, Qiagen, and Cepheid (Danaher) Among Others",
      "id": 136604156,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Opportunities in the hemato-oncology testing market include rising lymphoma and myeloma cases, personalized therapy demand, and advanced molecular diagnostics. Emerging technologies like single-cell sequencing and long-read sequencing enhance diagnostic precision, thus driving market growth and improving patient outcomes. Hemato Oncology Testing Market Hemato Oncology Testing Market Dublin, Sept. 02, 2025 (GLOBE NEWSWIRE) -- The \"Hemato-Oncology Testing Market Size, Share & Trends Analysis 2025-",
      "url": "https://finnhub.io/api/news?id=0997936512655a16c9459c76ec16c3092746a3f3b6a86ea25ed3178d34210670"
    }
  },
  {
    "ts": null,
    "headline": "Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth",
    "summary": "Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (\"Defence\" or the \"Company\"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the engagement of Amie Phinney, PhD, MBA as the Strategy & Business Advisor, effective immediately. Dr. Phinney will work closely with senior leadership to refine and align the company's short- and long-term strategies as it pursues exciting new...",
    "url": "https://finnhub.io/api/news?id=53dd669d1b66939b47a4b02c467a9c1d461492c09a4e72b4b653c3cc05a3d3c0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756800900,
      "headline": "Defence Therapeutics Engages Dr. Amie Phinney as Strategy & Business Advisor to Guide Next Phase of Growth",
      "id": 136604157,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "Montreal, Quebec--(Newsfile Corp. - September 2, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) (\"Defence\" or the \"Company\"), a leading biotechnology company specialized in drug delivery technologies, is pleased to announce the engagement of Amie Phinney, PhD, MBA as the Strategy & Business Advisor, effective immediately. Dr. Phinney will work closely with senior leadership to refine and align the company's short- and long-term strategies as it pursues exciting new...",
      "url": "https://finnhub.io/api/news?id=53dd669d1b66939b47a4b02c467a9c1d461492c09a4e72b4b653c3cc05a3d3c0"
    }
  }
]